Summary In a population-based study of 115 children with non-B-cell acute lymphoblastic leukaemia, we analysed the relation of the degree of leukopenia and risk of relapse to the degree of hepatotoxicity (as measured by serum aminotransferase (AT)) during oral methotrexate (MTX) and 6-mercaptopurine (6MP) maintenance chemotherapy (MT). Hepatotoxicity was calculated as a mean of all AT-measurements (mATMT). Lack of hepatotoxicity was defined as a mATMT < 40 IU I -. A highly significant correlation was demonstrated between the mean AT during the first, second, and third year of MT (r > 0.70, P < 0.00001). mATMT was not related to the mean WBC during MT (r = -0.03, P = 0.36), but was related to the rise in WBC following cessation of therapy (r = 0.24, P = 0.06). Patients with recurrent disease had significantly lower mATMT than patients staying in remission (P = 0.03 for both over-all and haematological relapse risk (Figure 1) . One hundred and twenty-eight patients completed induction and consolidation therapy. Of these, 13 were excluded from this study due to major protocol violation during induction or consolidation therapy, refusal of MT by parents, AT not measured during MT, or lack of data (3, 1, 7 and 2 patients). Thus, 115 patients (67 boys and 48 girls) were eligible for analyses, with 56 cases of standard risk (SR), 39 cases of daily for 4 days); 6MP = oral 6-mercaptopurine (75 mg m-2 day-'); MTX = oral methotrexate (20 mg m-2 week-'); M = intrathecal methotrexate (12 mg m 2); pred/p = oral prednisone (60 mg m-2 day-'); -= 6-thioguanine (60 mg m 2 day-'); | / M = 500/1,000 mg MTX 24 h infusion with leucovorin rescue; V = vincristine (2 mg m2, max. 2 mg dose-'); XXXX = CNSirradiation (2,400 cGy).
Summary In a population-based study of 115 children with non-B-cell acute lymphoblastic leukaemia, we analysed the relation of the degree of leukopenia and risk of relapse to the degree of hepatotoxicity (as measured by serum aminotransferase (AT)) during oral methotrexate (MTX) and 6-mercaptopurine (6MP) maintenance chemotherapy (MT). Hepatotoxicity was calculated as a mean of all AT-measurements (mATMT). Lack of hepatotoxicity was defined as a mATMT < 40 IU I -. A highly significant correlation was demonstrated between the mean AT during the first, second, and third year of MT (r > 0.70, P < 0.00001). mATMT was not related to the mean WBC during MT (r = -0.03, P = 0.36), but was related to the rise in WBC following cessation of therapy (r = 0.24, P = 0.06). Patients with recurrent disease had significantly lower mATMT than patients staying in remission (P = 0.03 for both over-all and haematological relapse risk). Patients with a mATMT >40 IU 1' had a lower risk of relapse than patients with a mATMTA40 IU 1-' (4.5 year CCR: 0.70 and 0.50, P = 0.06; and 4.5 year haematological remission: 0.83 and 0.63, P = 0.03). The favourable outcome for patients with hepatotoxicity could be demonstrated for all risk groups.
Methotrexate (MTX) and 6-mercaptopurine (6MP) are potential inducers of liver damage, and pathological liver function tests and biopsies are frequently encountered with oral MTX and 6MP maintenance therapy (MT) for childhood acute lymphoblastic leukaemia (ALL) (Nesbit et al., 1976; McIntosh et al., 1977; Topley et al., 1979; Parker et al., 1980; Menard et al., 1980; Harb et al., 1983) . As the chance for long-term disease-free survival improves, chronic side effects of therapy like liver dysfunction gains increasing importance. However, recurrent disease still remains the major risk for these children, and dose reductions or withdrawal of therapy in case of abnormal liver function tests could well be more harmful that continued treatment. Recognising the large inter-individual variations in the pharmacokinetics of oral MTX and 6MP Lennard et al., 1983; Schmiegelow et al., 1990) , the degree of hepatotoxicity may reflect the magnitude of systemic drug exposure, i.e. the impact of therapy, as have been indicated by some studies (Parker et al., 1980; Schmiegelow et al., 1990) , and hepatoxicity could thus be a possible favourable feature in respect to prognosis.
In the present population-based study of non-B-cell ALL in children > 1 year of age, we have analysed hepatotoxicity (measured by the rise in aspartate or alanine aminotransferases (AT)) during MT, and its relation to drug dosage and to myelodepression (measured by the mean white cell count), as well as its relation to relapse risk. Itermediate risk- daily for 4 days); 6MP = oral 6-mercaptopurine (75 mg m-2 day-'); MTX = oral methotrexate (20 mg m-2 week-'); M = intrathecal methotrexate (12 mg m 2); pred/p = oral prednisone (60 mg m-2 day-'); -= 6-thioguanine (60 mg m 2 day-'); | / M = 500/1,000 mg MTX 24 h infusion with leucovorin rescue; (Simon & Wittes, 1985) . Therapy Therapy depended on risk classification (Figure 1 ). MT with weekly oral MTX (target dose: 20 mg m2 ) and daily oral 6MP (target dose: 75 mg mr2) was started 10-12 weeks from remission with dose adjustments determined by blood counts (target WBC: 1.5-4.0 x 109 1-') and presence of toxicity. Drug dosage was reduced for WBC <1.5 x 109 1-', both drugs being withdrawn at WBC < 1.0 x 109 1-'. All patients with IR-ALL received 3-5 cycles of alternating therapy of reinductions or 24 h intravenous high dose MTX-infusions (HDM) at 4-week intervals during the first 6-9 months of MT. In addition, patients with IR-ALL diagnosed before 1983 (11 patients) and all patients with HR-ALL received reinductions every third month throughout MT. Therapy was for all patients discontinued after three years of CCR.
Patients and methods

Patients
During MT and for at least 12 months after cessation of therapy, haemoglobin, white cell (WBC) and platelet counts were done at least monthly. Routine absolute neutrophile counts (ANC) were not part of the protocols. ANC were determined together with WBC for 59 patients. AT was measured regularly during MT, but the intervals between sampling differed. AT was for 17 patients measured together with blood counts; i.e. at least monthly. For 63 patients, AT was measured every 6-8 weeks, and for the remaining 25 patients at longer intervals (median interval: 4 months). AT was determined as described elsewhere (Scandinavian Committee on Clinical Chemistry, 1974). Bone-marrow and spinal fluid tests were done before the cessation of therapy, every third month for the first year off treatment, and beyond this only at suspicion of relapse. Cases of haematological relapse include relapses in combination with extramedullary disease. CNS (central nervous system) and testicular relapses are all isolated relapses, and are counted as censoring observations in respect to haematological remission (Simon & Wittes, 1985) .
Drug dosage
For each patient, the average dose of MTX and 6MP per m2 were calculated as the cumulated prescribed dose per m2 divided by the period from start of MT until relapse, cessation of therapy or end of follow-up, whichever came first. The duration of withdrawal of MTX and 6MP during MT due to toxicity or febrile illness were calculated as a percentage of the length of MT.
WBC
For every patient, a mean WBC was calculated for the period of MT until relapse, end of therapy or end of followup (mWBCMT). For patients completing MT, a mean WBC was calculated for the third year of MT (mWBC3y). They were calculated as weighted means of all WBC measurements: mWBCMT = (M4WBC. x (D.,+I -Df))/LMT, mWBC3y F (I4FWBC, x (D, + -Dn))/365, where WBCn is the white cell count at date n, DF and DL are the first and the last days of the period included in the analyses, and LMT iS the length of MT. Thus, each WBC was weighted according to the intervals between sampling. For patients being at least 10 months off therapy in first remission, a mean WBC after cessation of therapy (mWBC0ff) Due to persistent, severe hepatotoxicity, oral MTX was in 13 patients substituted with oral cyclophosphamide (100mg m-2day-'). These patients were all censored at the time of cyclophosphamide/MTX subsititution (Simon & Wittes, 1985) .
Statistical analyses
Cox proportional hazards regression analysis with maximum partial likelihood ratio tests was applied to a set of variables to detect possible prognostic factors as well as the combined and independent significance of these (Cox, 1972) . In the stepwise multivariate analysis, additional parameters were included in the combined model only if their level of significance was <0.10. The Kaplan -Meier method was applied to estimate remission duration and to generate relapse-free survival curves (Kaplan & Meier, 1958) . Remission duration of subgroups were compared with the generalised Savage test (Mantel, 1966) .
Results
The median mATMT was 48 IU 1I (range: 17-287) ( Figure  2) . Forty patients had a mATMT .40 IU -'. Nine of these 40 patients never had an AT of >40IUI-' during MT, whereas intermittent rises in AT of >40 IU 1-were found in the remaining 31 patients.
For the total material there was no significant differences in the prevalence of hepatotoxicity during the first, second, and third year of MT (median values for mAT1y = 53, mAT2y= 50, mAT3y=49 IU I-'). Neither risk group (which includes previous therapy), gender, or age significantly influenced mATMT, and there was no significant relation between mATMT and the interval between samplings, although there was a trend towards patients with hepatotoxicity having AT measured at shorter intervals than patients with normal AT.
A highly significant intra-individual correlation between the degree of hepatotoxicity during the first, second, and third year of MT could be demonstrated (Figure 3) Patients who relapsed had significantly lower mATMT than patients staying in remission (Wilcoxon's rank sum test: any relapse, P = 0.03; haematological relapse, P = 0.03).
Stepwise multivariate regression analyses were done to explore the prognostic significance of combinations of possible relapse predictors and to define a 'best-fit' model to predict relapse. The variables analysed were: year of diagnosis (1981-83 = 1 vs 1984-85 = 2), gender (male = 1, female = 2), age at diagnosis, WBC at diagnosis, the average dose of MTX and 6MP, mWBCMT, and presence of hepatotoxicity (mATMT < 40 I 1-= 1, mATMT > 40 IU 1-' = 2). The bestfit model to predict haematological relapse included hepatotoxicity and mWBCMT (global P value <0.02). The best-fit model to predict any relapse included gender and hepatotoxicity (global P value <0.002). The coefficients of the covariates included in the models and their P values as uni-and covariates are given in Table III . Identical 'best-fit' models were achieved with stepwise backward elimination, all covariates being forced into the model at the first step. Figure 4 illustrates the positive relation between mATMT and the probability of staying in remission. Figure 5 gives Kaplan-Meier plots for the risk of haematological or any relapse for patients stratified by a mATMT >40IUI-' or < 40 IU 1-'. Patients with a mATMT < 40 IU I-' had a significantly poorer outcome than did patients with mATMT >40 IU 1-' with a 4.5 year probability of staying in haematological remission of 0.63 and 0.83 (P = 0.03), and a 4.5 year probability of CCR of 0.50 and 0.70 (P = 0.06). The favourable prognosis for patients with a mATMT > 40 IU 1' existed for all three risk groups, but was statistically significant only in respect to haematological relapse for SR patients (Table IV) . A time-dependency of the prognostic value of hepatotoxicity (i.e. a difference in the clinical significance of hepatotoxicity during the first, second and third years of MT) could not be demonstrated.
Discussion
The present study has confirmed the results of previous reports of a high prevalence of hepatotoxicity in leukaemic children receiving oral MTX/6MP therapy. Whereas a number of these studies have set focus on the relation between pathological liver function tests and the presence of an abnormal liver histology (Nesbit et al., 1976; McIntosh et al., 1977; Topley et al., 1979) , the main purpose of the present study was to explore the relation between relapse risk and the rise in serum AT, the most commonly applied test to detect liver dysfunction used by the departments participating in the study.
The significant correlation between a rise in serum AT and a reduced relapse risk could have several explanations, alone or combined.
The large inter-individual differences in plasma concentration profiles after oral MT implies different intensity of therapy, and children with adverse pharmacokinetic parameters might lack hepatotoxicity and be at increased risk for relapse, due to reduced systemic drug exposure to both liver and lymphoblasts (Pinkel et al., 1971; Craft et al., 1981) . In support of hepatotoxicity reflecting treatment intensity, we found a relation between mATMT and the rise in white cell counts following cessation of therapy. In addition, a correlation of hepatotoxicity to red blood cell and hepatic accumulation of MTX-polyglutamates has been demonstrated for MTX-therapy of leukaemia and psoriasis (Schmeigelow et al., 1989; Hendel, 1985) . Finally, patients with hepatoxicity seem to have delayed systemic clearance of MTX (Parker et al., 1980) . If hepatotoxicity does reflect treatment intensity, reduction of the doses of MTX and 6MP for patients with abnormal liver function tests could carry an increased relapse risk (Pinkel et al., 1971) , which was also indicated by the present study.
6MP undergoes hepatic metabolism and the first-pass effect is considerable (Zimm et al., 1983) . MTX-induced hepatotoxicity, whether or not due to increased intestinal absorption or reduced clearance, could therefore impair 6MP breakdown, leading to treatment intensification. Along this line it has been demonstrated that 6MP plasma peak-concentration and AUC are increased with concurrent administration of MTX and 6MP, compared to 6MP given alone (Balis et al., 1987) .
Another metabolic explanation could be changes in the activity of enzymes involved in MTX and 6MP metabolism Lennard & Lilleyman, 1987; Rodenhuis et al., 1987) . Zimm et al. (1986) (Schmiegelow et al., 1990) .
The relation between hepatotoxicity and relapse risk could be due to a prolonged effect of previously given hepatotoxic drugs, which could have influenced the amount of residual Step 0 Step I
Step 0 Step (Peeters et al., 1988) . In the present material we found no difference in the dose of MTX for patients with mATMT < 40 or >40 IU 1'. Neither did the two groups differ in respect to the degree of leukopenia (mWBCMT) the parameter most widely used to adjust MT. Thus, there was no indication that patients lacking hepatotoxicity were treated too leniently.
Other potentially hepatotoxic events like previous given drugs, general anaesthesia (GA) or hepatitis could have influenced the prevalence of rises in AT. However, as therapy and the frequency of GA were the same for all patients within the risk groups, and AT was the only abnormal liver function test (among prothrombin time, bilirubin, phosphatase and AT) for >90% of the patients with mATMT >40 IUI-1, these factors hardly significantly influenced the relation between rises in AT and risk of relapse.
A major question is whether downward dose adjustments are justified in the case of hepatotoxicity. A number of previous reports have indicated a high incidence of serious liver damage, but most of these patients received far higher doses than presently used (Parker et al., 1980) . The rises in liver enzymes during MT are in most cases mild and transient with normalisation within a few months following the cessation of therapy. For patients with severe liver dysfunction with affected prothrombin time, jaundice or very high levels of liver enzymes, a liver biopsy may offer a guide to whether dose modifications should take place, though often no correlation exists between pathological liver function tests and histology (Topley et al., 1979) . Parker et al. (1980) suggested that analysing plasma concentration profiles of drugs could be helpful in determining dose modifications. However, one should bear in mind that patients with delayed drug clearance might be receiving the better treatment, which could be jeopardised by dose reductions.
Until prospective studies have demonstrated that hepatotoxicity is a greater threat to patients than the risk of relapse, dose reductions do not seem warranted unless serious liver damage have been confirmed by histology.
